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Greg P Rubin, Jon D Emery
Summary
Background Pancreatic cancer is the tenth most common cancer in the UK; however, outcomes are poor, in part due 
to late diagnosis. We aimed to identify symptoms and other clinical and sociodemographic factors associated with 
pancreatic cancer diagnosis and diagnostic intervals.
Methods We did this prospective cohort study at seven hospitals in two regions in England. We recruited participants 
aged 40 years or older who were referred for suspicion of pancreatic cancer. Data were collected by use of a patient 
questionnaire and primary care and hospital records. Descriptive and regression analyses were done to examine 
associations between symptoms and patient factors with the total diagnostic interval (time from onset of the fi rst 
symptom to the date of diagnosis), comprising patient interval (time from fi rst symptom to fi rst presentation) and 
health system interval (time from fi rst presentation to diagnosis).
Findings We recruited 391 participants between Jan 1, 2011, and Dec 31, 2014 (24% response rate). 119 (30%) 
participants were diagnosed with pancreatic cancer (41 [34%] had metastatic disease), 47 (12%) with other cancers, 
and 225 (58%) with no cancer. 212 (54%) patients had multiple fi rst symptoms whereas 161 (41%) patients had a 
solitary fi rst symptom. In this referred population, no initial symptoms were reported more frequently by patients 
with cancer than by those with no cancer. Several subsequent symptoms predicted pancreatic cancer: jaundice 
(51 [49%] of 105 patients with pancreatic cancer vs 25 [12%] of 211 patients with no cancer; p<0·0001), fatigue 
(48/95 [51%] vs 40/155 [26%]; p=0·0001), change in bowel habit (36/87 [41%] vs 28/175 [16%]; p<0·0001), weight loss 
(55/100 [55%] vs 41/184 [22%]; p<0·0001), and decreased appetite (41/86 [48%] vs 41/156 [26%]; p=0·0011). There was 
no diff erence in any interval between patients with pancreatic cancer and those with no cancer (total diagnostic 
interval: median 117 days [IQR 57–234] vs 131 days [IQR 66–284]; p=0·32; patient interval 18 days [0–37] vs 15 days 
[1–62]; p=0·22; health system interval 76 days [28–161] vs 79 days [30–156]; p=0·68). Total diagnostic intervals were 
shorter when jaundice (hazard ratio [HR] 1·38, 95% CI 1·07–1·78; p=0·013) and decreased appetite (1·42, 1·11–1·82; 
p=0·0058) were reported as symptoms, and longer in patients presenting with indigestion (0·71, 0·56–0·89; 
p=0·0033), back pain (0·77, 0·59–0·99; p=0·040), diabetes (0·71, 0·52–0·97; p=0·029), and self-reported anxiety or 
depression, or both (0·67, 0·49–0·91; p=0·011). Health system intervals were likewise longer with indigestion 
(0·74, 0·58–0·95; p=0·0018), back pain (0·76, 0·58–0·99; p=0·044), diabetes (0·63, 0·45–0·89; p=0·0082), and 
self-reported anxiety or depression, or both (0·63, 0·46–0·88; p=0·0064), but were shorter with male sex 
(1·41, 1·1–1·81; p=0·0072) and decreased appetite (1·56, 1·19–2·06; p=0·0015). Weight loss was associated with 
longer patient intervals (HR 0·69, 95% CI 0·54–0·89; p=0·0047).
Interpretation Although we identifi ed no initial symptoms that diff erentiated people diagnosed with pancreatic cancer 
from those without pancreatic cancer, key additional symptoms might signal the disease. Health-care professionals 
should be vigilant to the possibility of pancreatic cancer in patients with evolving gastrointestinal and systemic 
symptoms, particularly in those with diabetes or mental health comorbidities.
Funding National Institute for Health Research and Pancreatic Cancer Action.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
Pancreatic cancer is the tenth most common cancer in the 
UK, accounting for 3% of all new cancers in 2012.1 
Incidence of the disease is rising, refl ecting both an ageing 
population and an increased prevalence of obesity and 
diabetes.2 No eff ective screening methods are yet available, 
and most cases of pancreatic cancer have already invaded 
local structures or metastasised by the time patients are 
diagnosed.3 Survival from pancreatic cancer is very poor, 
with less than 5% of patients alive at 1 year.1 Despite 
advances in treatment and outcomes, a 10-year survival of 
1% has remained unchanged for more than 40 years.1
The diagnostic pathway for pancreatic cancer 
comprises a series of stages or intervals that each 
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contribute to the overall period of time between onset 
of symptoms and initiation of treatment.4 The total 
diagnostic interval comprises the patient interval (from 
onset of fi rst symptom to fi rst health-care consultation) 
and the health system interval (from fi rst consultation via 
referral and investigations to diagnosis and initiation of 
treatment);4 shorter patient and health system intervals 
are associated with longer survival.5 In the past few years, 
reports have suggested that both intervals are longer for 
pancreatic cancer than for other common cancers, such 
as lung or urological cancer.6–9
Patients with pancreatic cancer can be symptomatic for 
many months before presentation.10 Not all individuals 
interpret their initial symptoms as serious, and some 
attribute them to ageing, lifestyle, or other comorbidities 
(Mills K, unpublished).11 International comparisons 
suggest perceived barriers to symptomatic presentation 
were highest in the UK;12 other potential infl uences 
include negative beliefs about cancer outcomes,13 and 
poor awareness of the risk of cancer.14,15
The pathway to diagnosis in primary care can be 
complex, with delays arising when presentation is 
complicated by comorbidities, when referral is delayed 
or declined, or from false-negative investigation.16 
Symptoms of possible pancreatic cancer much more 
commonly arise from benign or self-limiting disorders, 
and general practitioners (GPs) face a considerable 
challenge to assess patients whilst making effi  cient use 
of hospital-based resources. Much of the evidence about 
the predictive value of symptoms for cancer or their 
association with later diagnosis is from retrospective 
studies, or from general practice datasets,17–19 which are 
limited by quality of data recording. Little is known about 
the diagnostic pathways of people with pancreatic cancer 
or symptoms that are associated with less timely 
diagnosis. We therefore recruited a prospective cohort of 
patients with symptoms suggestive of pancreatic cancer 
near to the point of their referral, and investigated the 
symptoms and other clinical and sociodemographic 
factors associated with pancreatic cancer diagnosis and 
diagnostic intervals. We postulated that the diagnostic 
intervals would vary by symptoms and other patient 
factors.
Methods
Study design and patients
The SYMPTOM pancreatic study was done alongside the 
SYMPTOM lung20 and colorectal21 studies. We recruited 
patients from seven hospitals in the East (n=6) and 
North East (n=1) of England.
Potential participants were identifi ed when referred to 
hospital via routine or urgent routes to a gastroenterology 
or hepatopancreatobiliary clinic, or relevant ultrasound 
departments. Referral letters were reviewed by a research 
nurse to identify patients aged 40 years or older whose 
referral mentioned one or more symptoms from a 
prespecifi ed list of symptoms associated with pancreatic 
cancer (appendix). These patients were sent an 
information sheet, the questionnaire, and a reply-paid 
envelope. Patients were ineligible if they were already 
undergoing treatment for any cancer or had serious 
mental or physical disease deemed unsuitable for 
questionnaire completion. No reminder letters were 
sent to non-responders. A subsample of patients were 
recruited for a qualitative interview study; these results 
will be reported separately.
We obtained National Health Service (NHS) ethics 
approval (10/H0306/50) and clinical governance 
approval. All patients provided written informed consent 
with returned questionnaires. 
Research in context 
Evidence before this study
We searched PubMed with the MeSH terms “symptom”, 
“diagnosis”, “pancreatic cancer”, and “interval” for all reports 
published before Dec 31, 2015. Little evidence exists for 
symptomatic presentations preceding a pancreatic cancer 
diagnosis: a US population-based case-control study identifi ed 
common gastrointestinal symptoms associated with pancreatic 
cancer, and a qualitative study from the UK showed that 
symptoms of an intermittent nature might precede a pancreatic 
cancer diagnosis. No studies could be directly compared with our 
research because none reported factors associated with 
pancreatic cancer diagnosis and diagnostic intervals.
Added value of this study
We identifi ed no fi rst symptoms that aid identifi cation of 
pancreatic cancer in people referred to hospital for suspicion of 
pancreatic cancer. However, as symptoms evolve, some 
subsequent symptoms can predict the diagnosis, such as 
jaundice, fatigue, change in bowel habit, weight loss, decreased 
appetite, and feeling diff erent. Time to diagnosis was shorter in 
people with jaundice and decreased appetite as fi rst symptoms, 
but was longer in people with comorbidities such as diabetes 
and common mental health problems. 
Implications of all the available evidence
Our fi ndings suggest that only people presenting with jaundice 
and decreased appetite as an initial symptom are investigated 
promptly. Primary care professionals could consider concurrent 
rather than sequential investigation, with CT and endoscopic 
ultrasound evaluation, of older people who present with 
indigestion that is atypical or associated with systemic symptoms. 
Health-care professionals could also have an increased awareness 
of the risk of pancreatic cancer in people with diabetes, and 
beware of misattributing potential symptoms of pancreatic 
cancer in those with mental health problems. The absence of 
strong symptom signals means that other strategies for early 
diagnosis, including the development of diagnostic biomarkers 
and improved access to imaging, are important.  
See Online for appendix
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Data collection
The SYMPTOM pancreatic questionnaire asked for the 
initial symptom noticed by the participant, and then 
enquired about specifi c symptoms relevant to pancreatic 
cancer as an initial or subsequent symptom (appendix). 
The remaining sections enquired about other symptoms 
and patient factors, including demographic characteristics 
and comorbidities.
Participants’ GPs completed a short proforma from 
the patient’s clinical record, including dates of the fi rst 
presentation with any of the ten specifi c symptoms 
within the previous 2 years, and the duration if recorded. 
We extracted data from hospital medical records for 
date and type of referral (urgent, routine, emergency, 
other); date of fi rst specialist consultation; dates of 
investigations and their fi ndings; date of diagnosis 
(histological, clinical); and dates of all multidisciplinary 
team meetings and their clinical decisions. Data 
extraction took place a minimum of 6 months after 
recruitment to ensure completion of investigation and 
initiation of treatment. We undertook double data 
extraction of a 5% sample of selected hospital data 
(dates of referral, fi rst appointment, diagnosis, stage) 
and confi rmed an acceptable level of agreement (>80% 
agreement for dates; >90% for diagnosis and stage).
We based our data collection, analysis, and reporting 
on the Aarhus statement for the conduct of cancer 
diagnostic studies,4 and STROBE guidelines for reporting 
observational studies.22
Procedures
When available we used the date on the fi rst confi rmatory 
histology report as the date of diagnosis4 for both cancer 
(International Classifi cation of Diseases codes 9–10) 
and non-malignant disorders, otherwise we used the 
date of diagnosis from the hospital medical record, 
including the outcomes of multidisciplinary team 
meetings. We categorised pancreatic cancer staging by 
TNM status at diagnosis when possible.23 When more 
than one staging report was available, we used the 
preoperative staging, which informed the initial 
treatment decision. Stage data were categorised into 
resectable or locally advanced and metastatic.24,25 
Complex diagnoses or cases with incomplete data were 
agreed by an adjudication group of clinicians (BB, FMW, 
JDE, GPR).
Demographic details comprised sex; age (as a 
continuous variable); ethnic origin (white vs non-white); 
smoking status; educational status; occupational status; 
living alone; and postcode, which we used to assign 
groups to quintiles of the Index of Multiple Deprivation 
(from quintile 1 [least deprived] to quintile 5 [most 
deprived]).26 Clinical variables relating to comorbidities 
comprised gastrointestinal disease; respiratory disease; 
self-reported anxiety or depression, or both; heart disease; 
diabetes; and arthritis. Family history of cancer was also 
identifi ed (present vs absent).
All symptoms reported up to 2 years before diagnosis 
were included in the analysis.27 When provided, estimated 
dates were converted to exact dates with an adaptation of 
the C-SIM trial algorithm.28 We used exact dates when 
available and estimated dates otherwise. If a participant’s 
unprompted initial symptom matched their response to a 
question about specifi c symptoms, they were given the 
corresponding symptom code and assigned the earliest of 
the dates provided. A fi rst symptom and date of onset was 
thus identifi ed for each participant. Many participants 
reported more than one initial symptom, termed multiple 
initial symptoms. Subsequent symptoms were defi ned as 
any symptom occurring after an initial symptom, but 
before diagnosis.
We defi ned the total diagnostic interval, or time 
to diagnosis, as the time from onset of the fi rst 
n (%)
Pancreatic cancer 119 (30%)
Adenocarcinoma 98 (82%)
Pancreatic neuroendocrine tumour 9 (8%)
Ampullary carcinoma 8 (7%)
Adenosquamous carcinoma 3 (3%)
Mucinous carcinoma 1 (<1%)
Other cancer 47 (12%)
Oesophageal adenocarcinoma 12 (26%)
Cholangiocarcinoma and gallbladder carcinoma 11 (23%)
Duodenal adenocarcinoma 4 (9%)
Lymphoma 7 (15%)
Hepatic adenocarcinoma 4 (9%)
Metastases 3 (6%)
Colorectal adenocarcinoma 2 (4%)
Other* 4 (9%)
Non-cancer† 225 (58%)
Nil abnormal 35 (16%)
Hiatus hernia 28 (12%)
Gallstones 25 (11%) 
Gastritis, duodenitis, ulcer 22 (10%) 
Oesophagitis, Barrett’s oesophagus 20 (9%)
Upper gastrointestinal polyp 18 (8%) 
Intraductal papillary mucinous neoplasm 16 (7%)
Hepatitis (viral and other causes) 11 (5%) 
Liver disease (non-alcoholic) 10 (4%)
Cholecystitis 9 (4%)
Drug reaction 9 (4%)
Pancreatitis 9 (4%)
Pancreatic cyst (serous cystadenoma, pseudocyst) 8 (4%) 
Diverticular disease 6 (3%)
Gastro-oesophageal refl ux disease, clinical 4 (2%)
Alcoholic liver disease 2 (<1%)
Other 16 (7%) 
*Breast, sarcoma, cancer of unknown primary, leukaemia (n=1 each). †Percentages 
total more than 100% because patients might have had more than one diagnosis. 
Table 1: Diagnostic characteristics of participants (N=391) 
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symptom to date of diagnosis. When the date of fi rst 
presentation to health care was known, we also 
calculated the patient interval, defi ned as the time from 
fi rst symptom to fi rst presentation, and the health 
system interval, defi ned as the time from fi rst 
presentation to diagnosis.
Statistical analysis
343 new cases of pancreatic cancer were diagnosed in 
Anglia and North Tees in 2005. Our original power 
calculation was based on recruitment of 200 participants 
with pancreatic cancer and 800 participants without 
cancer to provide more than 80% power to detect an 
11% absolute diff erence in symptom prevalence 
(ie, 50% in cancer cases and 39% in non-cancer cases). 
Descriptive analyses were done for the group as a 
whole, and by diagnostic group for patients with 
pancreatic cancer, other intra-abdominal or upper 
gastrointestinal tract cancers (herein referred to as 
other cancer), and no cancer. The main analyses 
focused on comparisons between pancreatic cancer and 
no cancer, with secondary analyses of all cancers 
(ie, pancreatic cancer plus other cancer) versus no 
cancer. Diff erences in demographic and clinical 
characteristics between diagnostic groups were 
assessed with Fisher’s exact test and Wilcoxon rank-sum 
tests, as appropriate. Similarly, diagnostic intervals 
were compared between groups with a Wilcoxon 
rank-sum test. Clinically relevant demographics, 
comorbidities, symptoms present in the 2 years before 
diagnosis, and family history of cancer variables were a 
priori included in multivariable analyses to identify 
predictors of time to diagnosis. We excluded variables 
present in fewer than ten participants. We chose to 
analyse pancreatic cancer, other cancer, and no cancer 
groups collectively for all outcomes because at the time 
of presentation and referral the fi nal diagnosis was 
unknown. Cox models were used to model the 
diagnostic intervals. Age was included as a linear eff ect; 
we confi rmed that this was a reasonable assumption by 
adding a quadratic term to the model. Zero diagnostic 
intervals resulted from approximate dates and were 
included in the main analysis as half a day. We did 
analyses with Stata (version 13).
Role of the funding source
The funders of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had 
full access to all the data in the study and had 
fi nal responsibility for the decision to submit for 
publication.
Results
Between Jan 1, 2011, and Dec 31, 2014, 1543 people were 
approached, of whom 375 (24%) responded. 32 participants 
were reassigned to the pancreatic cohort from the 
SYMPTOM colorectal cohort, ten participants did not 
meet the eligibility criteria, and six participants had 
insuffi  cient data for analysis, leaving a fi nal cohort of 
391 participants. The demographics of responders were 
similar to those of non-responders (responders: 52% 
male [n=194], median age 69 years [IQR 62–77]; 
non-responders: 49% male [n=413], median age 69 years 
[58–78]; appendix). Recruitment was more challenging 
than anticipated in our original power calculation, and 
the fi nal total of cancer cases and non-cancer cases 
(excluding other cancers) provided more than 80% power 
to detect a 16% absolute diff erence.
Pancreatic 
cancer (n=119)
Other cancer 
(n=47)
No cancer 
(n=225)
p value for 
pancreatic vs 
no cancer
Sex 0·73
Male 57 (48%) 25 (53%) 113 (50%)
Female 62 (52%) 22 (47%) 112 (50%)
Age (years) 68 (42–93) 70 (47–89) 69 (40–89) 0·93
Highest education level 0·56
Degree or diploma 45 (38%) 19 (40%) 81 (36%)
A Level, GCSE, O Level 42 (35%) 14 (30%) 71 (32%)
Other, none, or missing 32 (27%) 14 (30%) 73 (32%)
Ethnic origin 0·30
White 119 (100%) 44 (94%) 221 (98%)
Other or missing 0 3 (6%) 4 (2%)
Smoking status 0·20
Current 7 (6%) 5 (11%) 25 (11%)
Ex-smoker 52 (44%) 23 (49%) 83 (37%)
Never or missing 60 (50%) 19 (40%) 117 (52%)
Deprivation (IMD quintile) 0·95
Least deprived 37 (31%) 17 (36%) 71 (32%)
2nd quintile 41 (34%) 15 (32%) 77 (34%)
3rd quintile 23 (19%) 8 (17%) 40 (18%)
4th quintile 13 (11%) 4 (9%) 26 (12%)
Most deprived 3 (3%) 3 (6%) 10 (4%)
Missing 2 (2%) 0 1 (<1%)
Comorbidities
Respiratory diseases* 17 (14%) 9 (19%) 38 (17%) 0·64
Heart disease 7 (6%) 9 (19%) 26 (12%) 0·12
Self-reported anxiety or 
depression, or both
14 (12%) 5 (11%) 39 (17%) 0·21
Gastrointestinal diseases† 23 (19%) 2 (4%) 35 (16%) 0·37
Diabetes 25 (21%) 4 (9%) 24 (11%) 0·014
Arthritis 21 (18%) 9 (19%) 62 (28%) 0·047
Any of the above 73 (61%) 24 (51%) 126 (56%) 0·36
Perceived family history risk
Diabetes 14 (12%) 6 (13%) 37 (16%) 0·27
Cancer 38 (32%) 16 (34%) 66 (29%) 0·62
Heart disease 20 (17%) 6 (13%) 63 (28%) 0·024
(Table 2 continues on next page)
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119 (30%) participants were diagnosed with pancreatic 
cancer, 47 (12%) with other cancers, and 225 (58%) 
with no cancer (table 1). 16 (4%) patients were diagnosed 
with an intraductal papillary mucinous neoplasm; 
although these lesions are managed as premalignant 
disorders, we excluded these patients from the cancer 
group. 112 (94%) pancreatic cancers were confi rmed by 
histology. 41 (34%) patients with pancreatic cancer 
had metastatic disease and 66 (56%) patients had 
non-metastatic disease; 12 (10%) patients had unstaged 
disease. The stage distribution for patients in our cohort 
who had pancreatic cancer was similar to the distribution 
for patients in the US National Cancer Database, in 
which 55·2% of patients had metastatic disease.29 
No similar data exist for England. Of participants with 
stage data, 82 (69%) patients were staged preoperatively 
with an intention to treat, whereas 25 (21%) had been 
staged postoperatively.
The diagnostic groups were similar in terms of sex, 
age, deprivation, education, ethnic origin, region, and 
smoking status (table 2). Compared with patients 
diagnosed with no cancer, those with pancreatic cancer 
were more likely to have diabetes and less likely to have 
arthritis (table 2).
Among the total cohort, 161 (41%) patients had a 
solitary initial symptom. 212 (54%) patients had multiple 
initial symptoms: 76 (19%) patients had two symptoms, 
63 (16%) patients had three symptoms, and 73 (19%) 
patients had four or more symptoms; 18 (5%) patients 
reported no initial symptoms. Across the total cohort 
the most common symptoms were indigestion (n=224 
[57%]), loss of appetite (n=207 [53%]), and fatigue (n=203 
[52%]), but these were reported as fi rst symptoms in 
only 136 (35%), 115 (29%), and 105 (27%) participants, 
respectively (table 3). Weight loss (n=175 [45%]), feeling 
diff erent (n=174 [45%]), and change in bowel habit (n=170 
[43%]) were also common symptoms, whereas jaundice 
(n=120 [31%]) and back pain (n=97 [25%]) were less 
commonly reported, and only reported as initial 
symptoms by 35 (9%) and 44 (11%) participants, 
respectively (table 3). Although not specifi cally enquired 
about in the questionnaire, a sizeable minority of patients 
reported a change in urine or stool colour, vomiting, 
unilateral torso pain, and bloating (table 3).
In this referred population, no initial symptoms were 
more frequently reported in the pancreatic cancer group 
than in the no cancer group; however, jaundice was more 
frequently reported in the all cancer group than in the no 
cancer group (table 3). Jaundice, change in urine or stool 
colour, fatigue, change in bowel habit, weight loss, 
decreased appetite, and feeling diff erent were more 
frequently reported as subsequent symptoms in people 
diagnosed with pancreatic cancer than in those with no 
cancer (table 4).
A total diagnostic interval could be calculated for 
373 participants (table 5). For patients with non-metastatic 
pancreatic cancer, the median total diagnostic interval for 
any fi rst symptom was 108 days (IQR 47–222) compared 
with 136 days (86–323) for patients with metastatic 
disease (p=0·13). There were no diff erences in the total 
Pancreatic 
cancer (n=119)
Other cancer 
(n=47)
No cancer 
(n=225)
p value for 
pancreatic vs 
no cancer
(Continued from previous page)
Referral route‡
General practitioner referral
Fast track 61 (51%) 26 (55%) 138 (61%)
Routine 2 (2%) 2 (4%) 50 (22%)
Unspecifi ed or missing 19 (16%) 3 (6%) 9 (4%)
Hospital admission 2 (2%) 1 (2%) 1 (<1%)
Hospital referral
Accident and emergency 14 (12%) 11 (23%) 14 (6%)
Tertiary 13 (11%) 2 (4%) 5 (2%)
Internal 8 (7%) 2 (4%) 7 (3%)
Bowel screening 0 0 1 (<1%)
Region 0·59
Cambridge 115 (97%) 43 (91%) 214 (95%)
North East 4 (3%) 4 (9%) 11 (5%)
Values are n (%) or median (IQR), unless otherwise specifi ed. A Level=Advanced Level. O Level=Ordinary Level. 
GCSE=General Certifi cate of Secondary Education. IMD=Index of Multiple Deprivation. *Asthma, chronic obstructive 
pulmonary disease, others. †Infl ammatory bowel disease, peptic ulcer, irritable bowel syndrome. ‡The p value for 
referral route is omitted because of incomplete information and some categories having very low frequencies.
Table 2: Sociodemographic characteristics
Pancreatic 
cancer 
(n=119)
All cancer* 
(n=166)
No cancer 
(n=225)
p value for 
pancreatic 
vs no 
cancer
p value for 
all cancer vs 
no cancer
Symptoms in questionnaire
Indigestion 32 (27%) 48 (29%) 88 (39%) 0·024 0·036
Decreased appetite 33 (28%) 46 (28%) 69 (31%) 0·57 0·53
Fatigue 24 (20%) 35 (21%) 70 (31%) 0·030 0·027
Feeling diff erent 25 (21%) 40 (24%) 62 (28%) 0·18 0·44
Change in bowel habits 32 (27%) 45 (27%) 50 (22%) 0·33 0·27
Weight loss 19 (16%) 25 (15%) 41 (18%) 0·60 0·41
Back pain 18 (15%) 22 (13%) 22 (10%) 0·14 0·28
Jaundice 14 (12%) 21 (13%) 14 (6%) 0·074 0·028
Other symptoms reported by participants
Nausea or vomiting 4 (3%) 8 (5%) 20 (9%) 0·056 0·12
Change in urine or stool 
colour
13 (11%) 13 (8%) 11 (5%) 0·037 0·23
Unilateral torso pain 6 (5%) 7 (4%) 13 (6%) 0·78 0·49
Other pain 3 (3%) 5 (3%) 11 (5%) 0·29 0·35
Bloating 3 (3%) 4 (2%) 11 (5%) 0·29 0·21
Acute gastrointestinal illness 3 (3%) 3 (2%) 10 (4%) 0·37 0·15
Data are n (%), unless otherwise specifi ed. Table shows symptoms present in ten or more participants, sorted by 
frequency in total cohort. Column percentages might total more than 100% because of multiple symptoms. 
*Pancreatic and other cancers.
Table 3: Initial symptoms 
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diagnostic interval, patient interval, or health system 
interval between people with pancreatic cancer and those 
with no cancer (table 5).
Jaundice and decreased appetite were associated with a 
shorter total diagnostic interval, whereas indigestion, back 
pain, diabetes, and self-reported anxiety or depression, or 
both, were associated with a longer total diagnostic 
interval (table 6). Weight loss was associated with a longer 
patient interval (table 6). Male sex and decreased appetite 
were associated with a shorter health system interval, 
whereas indigestion, back pain, feeling diff erent, diabetes, 
and self-reported anxiety or depression, or both, were 
associated with a longer health system interval (table 6).
Discussion
To our knowledge, this is the fi rst large prospective 
cohort study to investigate factors associated with 
diagnostic intervals for pancreatic cancer and compare 
them with people with similar symptoms found not to 
have cancer. No initial symptoms were associated with 
pancreatic cancer in this referred population, but a wide 
range of subsequent symptoms were associated with 
pancreatic cancer. Jaundice and appetite change were 
both associated with shorter total diagnostic intervals 
and health system intervals, suggesting that they are 
recognised more promptly by health-care professionals 
and investigated more quickly than other symptoms. By 
contrast, indigestion and feeling diff erent had longer 
health system intervals, suggesting they might be 
managed in other ways, including alternative diagnostic 
pathways or empirical treatments. Back pain, diabetes, 
and self-reported anxiety or depression, or both, were 
all associated with longer health system intervals, 
suggesting that health-care professionals might 
misattribute symptoms in these groups to other causes. 
Weight loss was the only symptom associated with a 
longer patient interval, perhaps showing that patients 
make alternative explanations for this symptom and 
delay seeking help.
Key strengths of this study were the prospective design, 
collection of data from several sources (patient reports, 
and primary care and specialist records), and compliance 
with recommendations in the Aarhus statement4 and 
STROBE guidelines.22 Because we were analysing 
patient-reported symptoms, we defi ned the date of onset 
of initial symptoms with patient-reported rather than 
primary care-reported date. Ideally, we would have 
recruited patients from primary care before referral; 
however, this approach would have major logistical and 
resource implications in the identifi cation of a large 
prospective cohort of patients with symptoms of possible 
pancreatic cancer in order to capture a suffi  cient number 
of patients with cancer. Instead, we recruited patients as 
early as possible in the hospital setting. This method had 
the added benefi t of allowing us to recruit patients 
referred from other specialists, and those presenting as 
emergencies, although we might have under-recruited 
this group when compared with routes to diagnosis data 
for 2013.30 We recruited patients with a broad range of 
socioeconomic, educational, and occupational levels, 
although our cohort had a slightly lower proportion of 
more deprived patients than in the national population. 
Our recruitment process meant that some patients 
transpired to have other upper gastrointestinal cancers 
and 16 people had intraductal papillary mucinous 
neoplasms.31 We do not consider this aspect a weakness, 
Pancreatic 
cancer 
All cancer* No cancer p value for 
pancreatic 
vs no cancer
p value for 
all cancer vs 
no cancer
Symptoms in questionnaire
Indigestion 29/87 (33%) 43/118 (36%) 45/137 (33%) 1 0·60
Decreased appetite 41/86 (48%) 51/120 (43%) 41/156 (26%) 0·0011 0·0067
Fatigue 48/95 (51%) 58/131 (44%) 40/155 (26%) 0·0001 0·0012
Feeling diff erent 32/94 (34%) 36/126 (29%) 36/163 (22%) 0·041 0·22
Change in bowel 
habits
36/87 (41%) 47/121 (39%) 28/175 (16%) <0·0001 <0·0001
Weight loss 55/100 (55%) 68/141 (48%) 41/184 (22%) <0·0001 <0·0001
Back pain 17/101 (17%) 25/144 (17%) 28/203 (14%) 0·50 0·37
Jaundice 51/105 (49%) 60/145 (41%) 25/211 (12%) <0·0001 <0·0001
Other symptoms reported by participants
Nausea or vomiting 3/115 (3%) 5/158 (3%) 7/205 (3%) NA 1
Change in urine or 
stool colour
10/106 (9%) 12/153 (8%) 4/219 (2%) 0·0032 0·0081
Data are n/N (%), unless otherwise specifi ed. Table shows symptoms present in ten or more participants, sorted by 
frequency in total cohort. The denominator (N) excludes patients that had the symptom as a fi rst symptom. NA=not 
applicable. *Pancreatic and other cancers.
Table 4: Subsequent symptoms 
Total diagnostic interval 
(days)
Patient interval (days) Health system interval 
(days)
Median (IQR) n p value 
vs no 
cancer
Median 
(IQR)
n p value 
vs no 
cancer
Median (IQR) n p value 
vs no 
cancer
By diagnostic group
Pancreatic 
cancer
117 (57–234) 117 0·32 18 (0–37) 106 0·22 76 (28–161) 106 0·68
All cancer 112 (56–245) 164 0·19 11 (0–37) 150 0·078 75 (29–169) 150 0·74
No cancer 131 (66–284) 209 ·· 15 (1–62) 190 ·· 79 (30–156) 190 ··
Total cohort 125 (66–268) 373 ·· 14 (0–55) 340 ·· 77 (29–160) 340 ··
By symptom
Jaundice 85 (44–161) 120 ·· 11 (2–33) 114 ·· 49 (23–95) 114 ··
Change in 
bowel habits
113 (56–238) 170 ·· 14 (2–54) 159 ·· 70 (27–148) 159 ··
Decreased 
appetite
114 (58–249) 207 ·· 13 (1–46) 190 ·· 75 (28–138) 190 ··
Feeling 
diff erent
124 (66–293) 174 ·· 12 (0–47) 163 ·· 83 (37–198) 163 ··
Weight loss 125 (70–238) 175 ·· 22 (3–65) 160 ·· 71 (34–141) 160 ··
Fatigue 131 (73–274) 203 ·· 15 (0–59) 181 ·· 77 (35–190) 181 ··
Indigestion 138 (85–308) 224 ·· 18 (0–61) 210 ·· 88 (37–196) 210 ··
Back pain 183 (99–325) 97 ·· 16 (0–76) 90 ·· 110 (49–264) 90 ··
Table 5: Total diagnostic interval, patient interval, and health system interval for any symptoms 
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rather, it serves to highlight the complexity and challenges 
in the diagnosis of pancreatic cancer, and how similarly 
diff erent gastrointestinal cancers can present.
The main limitation of our study is the response rate of 
24%; however, this is similar to the response rate in 
other prospective studies of lung and colorectal cancer 
symptoms.20,21 We contacted the target population during 
the course of their investigation and a possibility is that 
some people were not able to complete a questionnaire 
at this worrying time. We might have under-recruited 
people who presented as an emergency. However, the 
demographics of non-responders were similar to those 
of responders, and the proportion of patients with 
metastatic pancreatic cancer was similar to international 
data,29 suggesting that our cohort was reasonably 
representative. Although this was a large cohort for this 
diffi  cult-to-diagnose disease, we had insuffi  cient power 
to examine specifi c clusters of symptoms and their 
associations with outcomes. A much larger prospective 
study would be needed to gain suffi  cient power, although 
this would be logistically challenging to achieve.
A systematic review5 provided evidence of an association 
between shorter times to diagnosis and more favourable 
outcomes for some cancers, such as breast and colorectal 
cancer. For pancreatic cancer, two of the fi ve identifi ed 
studies reported a positive association, whereas three 
reported no association.5 Our study found that the median 
patient interval for the total cohort was 14 days and the 
median health system interval (combining primary and 
secondary care) was 77 days. Although we included both 
cancer and non-cancer cases, these fi ndings are similar to 
those from the National Audit of Cancer Diagnosis in 
Primary Care,9 which showed a median patient interval of 
19 days (IQR 1–61). The moderately long health system 
interval should be set in the context of high rates of 
multiple GP visits recorded in the National Patient 
Experience Survey for patients with pancreatic cancer.32 
The only UK primary care database study showed that 
jaundice was the most predictive symptom for pancreatic 
cancer; only one other symptom, weight loss, when 
present with another non-jaundice symptom, increased 
the positive predictive value to more than 2%.17 In our 
study, weight loss was an uncommon fi rst symptom 
but a common subsequent symptom; therefore, even 
participants with more than one initial symptom would 
not necessarily be considered to have an increased risk of 
pancreatic cancer. In our qualitative study (Mills K, 
unpublished) people described subtle changes in appetite 
and often attributed their symptoms to dietary choices or 
an acute illness, prompting changes in type and frequency 
of meals. Appetite loss was the only symptom associated 
with a shorter health system interval, suggesting that 
health-care professionals might also have been alert to the 
signifi cance of these changes.
Total diagnostic interval (n=370) Patient interval (n=337) Health system interval (n=337)
HR (95 CI) p value HR (95 CI) p value HR (95 CI) p value
Any symptom ·· ·· ·· ·· ·· ··
Indigestion 0·71 (0·56–0·89) 0·0033 0·79 (0·62–1) 0·051 0·74 (0·58–0·95) 0·018
Decreased appetite 1·42 (1·11–1·82) 0·0058 1·15 (0·88–1·49) 0·31 1·56 (1·19–2·06) 0·0015
Fatigue 1 (0·78–1·27) 0·97 0·88 (0·68–1·15) 0·35 1·03 (0·8–1·33) 0·83
Weight loss 0·84 (0·66–1·06) 0·15 0·69 (0·54–0·89) 0·0047 0·9 (0·7–1·17) 0·44
Feeling diff erent 0·93 (0·74–1·17) 0·52 1·24 (0·96–1·6) 0·096 0·75 (0·58–0·96) 0·024
Change in bowel habits 1·15 (0·91–1·45) 0·24 0·99 (0·78–1·26) 0·95 1·12 (0·87–1·44) 0·37
Jaundice 1·38 (1·07–1·78) 0·013 1·29 (0·99–1·68) 0·056 1·19 (0·91–1·55) 0·20
Back pain 0·77 (0·59–0·99) 0·040 0·85 (0·65–1·12) 0·25 0·76 (0·58–0·99) 0·044
Sex (ref=female) ·· ·· ·· ·· ·· ··
Male 1·23 (0·98–1·56) 0·080 0·93 (0·73–1·18) 0·55 1·41 (1·1–1·81) 0·0072
Age at diagnosis (10 years) 1·1 (0·98–1·22) 0·10 1·08 (0·97–1·22) 0·16 1 (0·9–1·12) 0·95
IMD quintile (ref=least deprived) ·· 0·51 ·· 0·42 ·· 0·35
2nd quintile 0·94 (0·73–1·22) ·· 0·87 (0·66–1·16) ·· 0·84 (0·63–1·1) ··
3rd quintile 1·17 (0·85–1·6) ·· 1·1 (0·79–1·53) ·· 1·08 (0·77–1·5) ··
4th quintile 1·23 (0·84–1·82) ·· 1·26 (0·84–1·9) ·· 0·97 (0·64–1·45) ··
Most deprived 0·91 (0·52–1·6) ·· 1·16 (0·66–2·06) ·· 0·68 (0·39–1·19) ··
Diabetes 0·71 (0·52–0·97) 0·029 1·06 (0·76–1·49) 0·72 0·63 (0·45–0·89) 0·0082
Gastrointestinal comorbidity 1 (0·74–1·37) 0·99 0·97 (0·69–1·35) 0·84 1·22 (0·88–1·69) 0·23
Self-reported anxiety or depression, 
or both
0·67 (0·49–0·91) 0·011 1·01 (0·73–1·41) 0·95 0·63 (0·46–0·88) 0·0064
Family history of cancer 0·81 (0·64–1·03) 0·083 0·93 (0·73–1·2) 0·59 0·79 (0·61–1·02) 0·067
Proportional hazards Cox model adjusted for all variables in the table plus smoking status (never vs current vs ex-smoker) and living alone (yes vs no). The model includes 
patients with all diagnoses. HR=hazard ratio. IMD=Index of Multiple Deprivation.
Table 6: Predictors of total diagnostic interval, patient interval, and health service interval 
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Our fi ndings show that there are subtle diff erences in 
the eff ect of symptoms and patient factors on patient 
and health system intervals, with some clear 
implications for policy makers and clinicians. That no 
initial symptoms were predictive of pancreatic cancer 
emphasises the challenges of triaging referrals for 
suspected pancreatic cancer. Although the alarm 
symptom jaundice was more frequently reported by 
patients in the all cancer group than by those with no 
cancer, it was reported as the fi rst symptom in less than 
12% of cases, and reported much more frequently as a 
subsequent symptom (43% of cases). We did not 
identify any other strong individual symptom signals of 
pancreatic cancer, suggesting that awareness campaigns 
should include messages that emphasise the importance 
of multiple, often intermittent, upper gastrointestinal 
symptoms (eg, decreased appetite and indigestion) and 
systemic symptoms (eg, fatigue and weight loss), and 
the evolution of symptoms over time.33 Revised NICE 
guidelines34 for early detection of pancreatic cancer 
support this premise, and have also lowered the 
threshold for referral.
Our study also shows that only people presenting with 
jaundice and decreased appetite as an initial symptom 
receive a diagnosis more promptly than do those 
presenting with other symptoms. Primary care 
professionals could consider concurrent rather than 
sequential investigation, with CT and gastroscopy, of 
older people who present with indigestion that is atypical 
or associated with systemic symptoms.35 Primary care 
professionals could also have an increased awareness of 
the risk of pancreatic cancer in people diagnosed with 
diabetes, particularly those with normal weight without 
the typical features predisposing to insulin resistance. All 
health-care professionals should remain alert to possible 
pancreatic cancer in people with back pain, and beware of 
misattributing potential symptoms of pancreatic cancer 
in those with self-reported anxiety and depression, or 
both. The increasingly widespread use of clinical decision 
support in primary care can also be informed by our 
fi ndings,36,37 but further research is needed, alongside GPs 
and specialists, to identify mechanisms by which patients 
can be identifi ed, referred, and diagnosed in the most 
timely and appropriate way. The absence of strong 
symptom signals means that other strategies for early 
diagnosis, including the development of diagnostic 
biomarkers and improved access to imaging, are 
important. Nevertheless, these data provide support for 
more targeted investigation of suspicious symptoms to 
identify pancreatic cancer at an earlier and more 
amenable stage.
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